placeholder ad

Erika D. Reynoso

Erika D. Reynoso

Sr. Scientific Director, US Medical Affairs, Rare Disease, Takeda

Erika Reynoso, PhD, is a results-driven seasoned biotechnology and pharmaceutical industry professional with expertise in Global and US Medical Affairs, primarily in rare diseases. She is Senior Scientific Director, Rare Disease within US Medical Affairs at Takeda, where she leads a team of Scientific Directors to partner with the VP and Medical Directors in the development and execution of the regional medical strategy across medical functions and cross-functionally in the therapeutic areas of rare bleeding disorders, lysosomal storage disorders, hereditary angioedema, post-transplant CMV infection, and related pipeline programs.

Previously, Erika worked at Biogen where she held various roles within Global Medical Affairs, including strategy and operations, medical training, medical information, congress strategy and execution, and Medical Directors’ office, across disease areas including hemophilia and other rare bleeding disorders, autoimmune disorders, spinal muscular atrophy, Alzheimer’s disease, and amyotrophic lateral sclerosis. Before Biogen, she was in Medical Affairs at Vertex Pharmaceuticals Incorporated, where she led the development of all medical/scientific publications activities for the HCV franchise. She began her career as a Senior Analyst at Health Advances, LLC, a strategy and research consulting firm focused exclusively on the life science and healthcare industries.

Erika holds a Ph.D. in immunology from Harvard University and a B.S. in microbiology, summa cum laude, from California State University Los Angeles. She is on the Board of Directors for Dedham Community House, a nonprofit organization that is dedicated to promoting local educational, recreational, and civic interests.


Scroll to Top